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Introduction
Ovarian hyperstymulation syndrome (OHSS) is rare
but potentially dangerous complication of assisted
reproductive techniques (ART). The iatrogenic form of
syndrome is an exaggerated response to gonado-
trophines used in ovulation induction.  The use of the
gonadotrophin releasing hormone (GnRH) agonist
long down-regulation protocol is associated with the
higher incidence of OHSS. The risk is increased in
younger women with low body weight and in the pres-
ence of polycystic ovaries (PCO). Spontaneous forms
of OHSS are very rare, always occur during pregnan-
cy, and are reported to develop between 8 and 14 week
of pregnancy when iatrogenic form usually starts ear-
lier, between 3 and 5 weeks of amenorrhea [1-4].
The pathophysiology of this condition is character-
ized by ovarian enlargement, massive extravascular
exudate accumulation in combination with profound
intravascular volume depletion and haemoconcentra-
tion. The underlying cause of these pathophysiological
changes remain unknown, but there are evidences that
vascular endothelial growth factor (VEGF), tumor
necrosis factor alpha (TNFα), interleukin 2 (IL-2) and
interleukin 6 (IL-6) contribute to the development of
syndrome [3,5,6]. 
The OHSS has traditionally been classified as mild,
moderate or severe. Milder forms are usually self lim-
ited and requires usually no further therapy other then
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observation. The severe form occurs in approximately
1-2% of IVF cycles [3,7,8]. 
The aim of the retrospective study was to present
management in moderate and severe iatrogenic ovarian
hyperstymulation syndrome in Department of Obstet-
rics and Gynecology in Central Clinical Hospital of
Ministry of Interior and Administration in Warsaw. 
Materials and methods
The study was performed in Department of Obstetrics and Gyne-
cology in Central Clinical Hospital of Ministry of Interior and
Administration in Warsaw and large outpatient infertility center
"Novum" in Warsaw between 14.07.2004 and 8.11.2005. Among
1306 consecutive cycles of ART performed, in 19 cases occur
moderate or severe iatrogenic ovarian hyperstymulation syndrome
and patients required hospitalization. As the result of total 1306
ovarian stimulation, 1281 ovarian punctures and 1237 intracyto-
plasmic sperm injections (ICSI) were done. Administration of
intravenous 20% albumin at the time of oocyte retrieval to prevent
OHSS was routine.
Subjects for the study were admitted to the Department of
Obstetrics and Gynecology in Central Clinical Hospital of Ministry
of Interior and Administration in Warsaw with moderate and severe
OHSS, according to the Golan criteria [9].
Nineteen women were admitted with massive ovarian enlarge-
ment, ascites, oliguria, in 12 cases liver dysfunction and in 3 cases
hydrothorax were present. No renal failure, hypovolemic shock,
adult respiratory distress syndrome (ARDS) was observed. None
of the patient died. 
Laboratory tests (blood sample taken to measure complete blood
count, serum protein, albumin, creatinine, urea, electrolytes, liver
enzymes, C - reactive protein (CRP), β-hCG, progesterone, estradi-
ol (E2), coagulation parameters; urine analysis) and ultrasound
examination of the ovarian size and ascites was done, abdominal cir-
cumference and body weight was measured. Vital signs (pulse,
blood pressure, temperature) were recorded every hour. 
Patients were treated with rehydration with intravenous crys-
talloids and volume expander such as hydroxyethyl starch (HES)
and albumin to achieve or maintain hemodynamic stability and
adequate urine output. 16 patients receive 20% albumin, minimal
dose was 100 ml and maximal was 4200 ml during hospitalization
(mean 1423.68 ml SD ±1319.23)  In 10 cases diuretics (furosemide
10mg intravenous daily) were used because of low urine output
after adequate intravascular volume restoration. In case of suspi-
cion of inflammatory state or after paracentesis patients were treat-
ed with antibiotics, usually semi-synthetic penicillin. Patients with
past history or laboratory findings putting them at high risk of
thrombosis also receive anticoagulants such as low molecular
weight heparin and used elasticated tubular stockings.  Ultrasound-
guided paracentesis from transabdominal approach was performed
when symptoms of ascites become severe (ascites causes pain and
compromised pulmonary function). In 11 patients paracentesis was
done, minimal volume of ascitic fluid removed daily was 500 ml,
maximal 2500 ml, 9 of woman require serial paracentesis to main-
tain adequate renal and pulmonary function (mean volume of
ascitic fluid removed during hospitalization was 2863, 15 ml, one
patient during 9 cycles of paracentesis loss 18600 ml ascitic fluid). 
In one patient occurred intra-abdominal hemorrhage from
ovarian rupture and laparotomy with oophorectomy was per-
formed.
Oral intake of water was restricted, monitoring of fluid intake
and output, and daily monitoring of body weight was performed.
During treatment controlled laboratory tests were done. All
patients were followed by serial ultrasound examination.
Laboratory tests results and clinical findings were reported as
mean and standard deviation. Statistical analysis was performed
using SPSS software package (SPSS Inc., Chicago, IL). 
Results
In our study 1.45% of patients undergoing assisted
reproductive technology (ART) program develop
moderate or severe ovarian hyperstymulation syn-
drome required hospitalization. The mean age of the
patients admitted to the ward was 31.2 years (SD
±3.90), mean duration of hospitalization was 20.6 day
(SD ±4.55). 
Mean laboratory test results, ovarian size in ultra-
sound examination, abdominal circumference and
amount of albumin and hydroxyethyl starch (HES)
transfused to the patient are presented in Table 1. 
Discussion
Severe ovarian hyperstymulation syndrome is a rare
but potentially life-threatening complication of phar-
macological ovarian stimulation. In the pathophysiol-
ogy of this syndrome the main mechanism is an
increase in capillary permeability of ovarian vessels
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Table 1. Mean laboratory results, ovarian size in ultrasound examination, abdominal circumference, and amount of albumin and hydrox-
yethyl starch (HES) transfused to the patient.
and other mesothelial surfaces resulting in fluid shift
from intravascular space to the third space compart-
ment. The pathogenesis of this condition is likely to be
multifactorial [10-18].
This state is responsible for the development of
symptoms of the syndrome such as ascites, pleural and
pericardial effusion, oliguria, hypovolemia and as the
result of haemoconcentration - thromboembolic events
[3,7,19,20].
Until now the only method proven to be effective in
prevention of OHSS is discontinuation of ovarian
stimulation and hCG administration to trigger ovula-
tion. There are suggestions about protective role of
albumin in reducing the incidence of severe OHSS, by
prevention the fluid shift to third space and binding
factors responsible for development of this syndrome,
but there is still debate on its value, because OHSS can
occur despite the use of albumin. In Gockmen et al.
study both HES and albumin significantly reduced the
incidence of moderate, severe and overall incidence of
OHSS. It is concluded that hydroxyethyl starch is a
cheaper and safer alternative to Human Albumin in
OHSS prevention. Albumin is also very useful in treat-
ment of OHSS as volume expander in severe cases
[3,8,21,22]. 
Continuous autotransfusion of ascitic fluid into the
systemic circulation as peritoneovenous shunting
(CATSA) in severe OHSS treatment was suggested by
Koike et al. The aim of this method was transfusing to
the patient her own proteins instead exogenous. How-
ever these may increase plasma levels of inflammato-
ry cytokines, thereby increasing capillary hyperperme-
ability and aggravating the extravascular fluid shifts.
Also risk of contamination during this procedure
increase its usability [1,23].
In cases with risk factors for OHSS stimulation
procedures can be modified and lutheal hCG exposure
can be minimized by using lutheal support with prog-
esterone in preference to hCG, or by freezing all
embryos. However freezing all embryos increases the
financial and emotional stress accompanying in vitro
fertilization. Reducing only the number of embryos
transferred to one, can be the way of preventing multi-
ple pregnancy and by that way, especially in woman of
high risk, incidence of severe ovarian hyperstymula-
tion syndrome can also be decreased [1,3].
It's also very important to monitor patient condition
to detect symptoms and signs of ovarian hyperstymu-
lation syndrome in early state and identify worsening
or complications during outpatient therapy. Frequent
evaluation include frequent physical and ultrasound
examination [3,24].
During treatment of severe OHSS careful and fre-
quent re-evaluation of the hospitalized patient is essen-
tial, because pain and ascites can mask ovarian rup-
ture, as it was in our case.
In case of severe OHSS required hospitalization
apart from medical treatment we should give psycho-
logical support to the patient [3,20].
In conclusion, it is very important to identify high
risk patients prior to assisted reproduction treatment
and choose appropriate therapy. Identification of all
risk factors and it's correlation with clinical features
require more large randomized studies but can be key
to preventing and managing this dangerous condition.
References
[ 1] Al-Shawaf T, Grudzinskas JG. Prevention and treatment of
ovarian hyperstymulation syndrome. Best Pract  Res Clin
Obstet Gynecol. 2003;17(2):249-61.
[ 2] Delbaere A, Smits G, Olatunbosun O et al. New insights into
the pathophysiology of ovarian hyperstimulation syndrome.
What makes the difference between spontaneous and iatro-
genic syndrome? Hum Reprod. 2004;19(3):486-9. 
[ 3] Mathur R, Evbuomwan I, Jenkins J. Prevention and manage-
ment of ovarian hyperstimulation syndrome. Current Obst
Gynaecol. 2002;12:111-6. 
[ 4] Taher BM, Ghariabeh RA, Jarrah NS et al. Spontaneous ovar-
ian hyperstimulation syndrome caused by hypothyroidism in
adult. Eur J Obstet Gynecol Reprod Biol. 2004;112:107-9.
[ 5] Barak V, Elchalal U, Edelstein M et al. Interleukin-18 levels
correlate with severe ovarian hyperstimulation syndrome.
Fertil Steril. 2004;82(2):415-20. 
[ 6] Orvieto R. Controlled Ovarian Hyperstimulation - An Inflam-
matory State. J Soc Gynecol Investig. 2004;11(7):424-6. 
[ 7] Aboulghar MA, Mansour RT. Ovarian hyperstimulation syn-
drome: classifications and critical analysis of preventive
measures. Hum Reprod. 2003;9(3):275-89.
[ 8] Isik AZ, Vicdan K. Combined approach as an effective
method in the prevention of severe ovarian hyperstimulation
syndrome. Eur J Obstet Gynecol Reprod Biol. 2001;97(2):
208-12. 
[ 9] Golan A, Ron-El R, Soffer Y, Weinraub Z, Caspi E, Ovarian
hyperstimulation syndrome: An update revive. Obstet
Gynecol. 1989;44:430-40. 
[10] D'Angelo A, Amso N. "Coasting" (withholding
gonadotrophins) for preventing ovarian hyperstimulation
syndrome.  Cochrane Database Syst Rev. 2002;(3):
CD002811. 
[11] Delvigne A, Rozenberg S. Systematic review of data con-
cerning etiopathology of ovarian hyperstimulation syndrome.
Int J Fertil Womens Med. 2002;47(5):211-26. 
[12] Enskog A, Henriksson M, Unander M et al. Prospective study
of the clinical and laboratory parameters of patients in whom
ovarian hyperstimulation syndrome developed during con-
trolled ovarian hyperstimulation for in vitro fertilization. Fer-
til Steril. 1999;71:808-14.
[13] Geva E, Jaffe RB. Role of vascular endothelial growth factor
in ovarian physiology and pathology. Fertil Steril. 2000;74:
429-38.
[14] Goldsman MP, Pedram A, Dominguez CE et al. Increased
capillary permeability induced by human follicular fluid: a
hypothesis for an ovarian origin of the hyperstimulation syn-
drome. Fertil Steril. 1995;63:268-72.
[15] Levin ER, Rosen GF, Cassidenti DL et al. Role of vascular
endothelial cell growth factor in ovarian hyperstimulation
syndrome. J Clin Invest. 1998;102:1978-85.
[16] McClure N, Healy DL, Rogers PA et al. Vascular endothelial
growth factor as capillary permeability agent in ovarian
hyperstimulation syndrome. Lancet. 1994;344:235-6.
107Diagnosing and management of OHSS
[17] Morris RS, Paulson RJ. Increased angiotensin-converting
enzyme activity in a patient with severe ovarian hyperstimu-
lation syndrome. Fertil Steril. 1999;71(3):562-563. 
[18] Pellicer A, Albert C, Mercader A et al. The pathogenesis of
ovarian hyperstimulation syndrome: in vivo studies investi-
gating the role of interleukin-1, interleukin-6, and vascular
endothelial growth factor. Fertil Steril. 1999;71:482-489.
[19] Abramov Y, Elchalal U, Schenker JG. Pulmonary manifesta-
tions of severe ovarian hyperstimulation syndrome: a multi-
center study. Fertil Steril. 1999;71:645-651.
[20] The Practice Committee of the American Society for Repro-
ductive Medicine. Ovarian hyperstimulation syndrome. Fertil
Steril. 2004;82,supl 1:S81-86.
[21] Abramov Y, Fatum M, Abrahamov D, Schenker JG. Hydrox-
yethylstarch versus human albumin for the treatment of
severe ovarian hyperstimulation syndrome: a preliminary
report. Fertil Steril. 2001;75(6):1228-1230.
[22] Gokmen O, Ugur M, Ekin M et al. Intravenous albumin ver-
sus hydroxyethyl starch for the prevention of ovarian hyper-
stimulation in an in-vitro fertilization program: a prospective
randomized placebo controlled study. Eur J Obstet Gynecol
Reprod Biol. 2001;96(2):187-192. 
[23] Koike T, Araki S, Minakami H et al. Clinical efficacy of peri-
toneovenous shunting for the treatment of severe ovarian
hyperstymulation syndrome. Hum Reprod. 2000;15(1):13-7.
[24] Borenstein R, Elhalah U, Lunenfeld B, Schwartz ZS. Severe
ovarian hyperstimulation syndrome: a reevaluated therapeutic
approach. Fertil Steril. 1989;51(5):791-795. 
108 A.J. Jakimuk et al.
